Connect your AI

Eli Lilly LLY Investing Cash Flow

Investing Cash Flow at other companies

PfizerPFE

$785M-76.0%

AmgenAMGN

-$716M-60.2%

Cardinal HealthCAH

-$181M+93.8%

MannkindMNKD

$18.73M+214%

Oruka Therapeutics, Inc.ORKA

-$14.44M-134%

McKessonMCK

-$269M-97.8%

Other financials

Income statement

Revenue$19.8B+55.5%

Gross profit$16.2B+54.4%

Net income$7.4B+168%

EPS (diluted)$8.26+170%

Balance sheet

Cash & equivalents$5.3B+70.8%

Total debt$43.4B+12.6%

Total equity$31.2B+97.9%

Total assets$116.58B+30.4%

Cash flow

Operating cash flow$5.3B+220%

CapEx$2.3B+54.0%

Free cash flow$3.0B+1,828%

Valuation

Market cap$1.07T+51.7%

Enterprise value$1.11T+49.3%

P/E42.3×-8.8×

P/S14.8×+1.6×

Profitability

Gross margin82.8%+1.1pp

Net margin35%+12.3pp

FCF margin16.4%+8.7pp

Returns & leverage

Return on equity107.6%+29.9pp

Debt / equity1.4×-1.1×

Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Eli Lilly's investing cash flow?: Eli Lilly (LLY) reported investing cash flow of -$3.92B in Q1 2026.
How has Eli Lilly's investing cash flow changed year-over-year?: Eli Lilly's investing cash flow decreased by 16.8% year-over-year, from -$3.35B to -$3.92B.
What is the long-term trend for Eli Lilly's investing cash flow?: Over 4 years (2021 to 2025), Eli Lilly's investing cash flow has grown at a 39.9% compound annual growth rate (CAGR), from -$2.87B to -$10.97B.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.